• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19)
BMJ Open. 2023 Jun 7;13(6):e067634. doi: 10.1136/bmjopen-2022-067634.ABSTRACTINTRODUCTION: The combination of checkpoint inhibition and cisplatin-based chemotherapy is investigated in muscle invasive bladder cancer (MIBC) and results from phase 2 trials have been presented. Intravesical BCG has been used for non-MIBC (NMIBC) in patients with carcinoma in situ and high-grade Ta/T1 tumours. BCG induces innate and adapted immune response and upregulation of PD-L1 in preclinical models. The proposed trial is intended to implement a new immuno-immuno-chemotherapy induction therapy for MIBC. The combination of BCG and checkpoint...
Source: Cancer Control - June 7, 2023 Category: Cancer & Oncology Authors: Ulf Petrausch Martin Spahn Martina Schneider Stefanie Hayoz Cyrill A Rentsch Sacha Rothschild Aurelius Omlin Richard Cathomas Source Type: research

The Future of Cancer Immunotherapy
This article describes three emerging, novel cancer immunotherapies: BITE, TIL and cancer vaccines are therapies that recognize specific targets on cancer cells and trigger a specific immune response. So far, not all tumor types can benefit from these approaches the best results have been observed in hematological malignancies, melanoma, and lung cancer. These novel biological products are currently being tested in several cancer centers in Switzerland, and physicians must be familiar with these procedures, as some of their patients might be treated with such therapies in the near future.PMID:36855886 | DOI:10.1024/1661-8157/a003975
Source: Praxis - March 1, 2023 Category: General Medicine Authors: Nicolas Mach Source Type: research

Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland
CONCLUSION: These results suggest that treatment with checkpoint inhibitors improves overall survival in patients with metastatic NSCLC and that PD-L1 expression could have a predictive value in patients treated outside of clinical trials. Further studies are needed to study the magnitude of the benefit of checkpoint inhibitors according to molecular NSCLC subtype.PMID:36787492 | DOI:10.57187/smw.2023.40039
Source: Swiss Medical Weekly - February 14, 2023 Category: General Medicine Authors: Valentina Allmann Daniela Dyntar Dirk Lehnick Marco Dressler Kristin Zeidler Philipp Niederberger Jeanne Godau Joachim Diebold Oliver Gautschi Source Type: research

Pages: 1  2  3  4  5